Jason Kolbert, Maxim Group (2/18/15) "Mesoblast Ltd. highlighted results from the 'Protocol 275' study. The study (which extended enrollment through a pediatric expanded access program) continue to show a clear and meaningful survival benefit among responding pediatric bone marrow transplant recipients. . .we believe that MSC-100IV (Prochymal) will not only be approved in children, but also ultimately adults, and that it will save lives. This is orphan- and fast-track status, and the drug could be on the market in the next two years as a commercial product in the U.S., in our opinion."
In line with BLA filing in 2016 for US market.
Please DYOR.
GLTAH - 2015
Some commentary - GVHD (Maxim)
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 171759 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |